Hugel Inc Asset Resilience Ratio

Latest as of June 2026: 29.08%

Hugel Inc asset resilience ratio. Hugel Inc (145020) has an Asset Resilience Ratio of 29.08% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Hugel Inc to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩346.63 Billion
≈ $234.91 Million USD Cash + Short-term Investments

Total Assets

₩1.19 Trillion
≈ $807.81 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Hugel Inc (2014–2025)

Asset resilience ratio of Hugel Inc from 2014 to 2025. This chart shows how Hugel Inc's Asset Resilience Ratio has changed over time. Read Hugel Inc (145020) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Hugel Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 145020 current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩346.63 Billion 29.08%
Total Liquid Assets ₩346.63 Billion 29.08%

Asset Resilience Insights

  • Very High Liquidity: Hugel Inc maintains exceptional liquid asset reserves at 29.08% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Hugel Inc Industry Peers by Asset Resilience Ratio

Compare Hugel Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Abivax SA
PA:ABVX
Biotechnology 2.58%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Disc Medicine Inc.
NASDAQ:IRON
Biotechnology 84.22%
Alpha Tau Medical Ltd
NASDAQ:DRTS
Biotechnology 65.79%
Galapagos N.V.
AS:GLPG
Biotechnology 86.45%

Hugel Inc Asset Resilience Ratio by Year (2014–2025)

Hugel Inc asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Hugel Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 30.56% ₩329.07 Billion
≈ $223.01 Million
₩1.08 Trillion
≈ $729.76 Million
-14.48pp
2024-12-31 45.04% ₩423.12 Billion
≈ $286.74 Million
₩939.44 Billion
≈ $636.64 Million
-6.82pp
2023-12-31 51.86% ₩481.93 Billion
≈ $326.60 Million
₩929.25 Billion
≈ $629.74 Million
+1.95pp
2022-12-31 49.91% ₩523.99 Billion
≈ $355.10 Million
₩1.05 Trillion
≈ $711.42 Million
-4.77pp
2021-12-31 54.68% ₩552.13 Billion
≈ $374.17 Million
₩1.01 Trillion
≈ $684.28 Million
-7.98pp
2020-12-31 62.66% ₩599.20 Billion
≈ $406.07 Million
₩956.34 Billion
≈ $648.10 Million
-0.92pp
2019-12-31 63.58% ₩568.80 Billion
≈ $385.47 Million
₩894.69 Billion
≈ $606.32 Million
-1.93pp
2018-12-31 65.51% ₩601.56 Billion
≈ $407.67 Million
₩918.27 Billion
≈ $622.30 Million
-7.05pp
2017-12-31 72.56% ₩595.69 Billion
≈ $403.69 Million
₩820.93 Billion
≈ $556.33 Million
+37.19pp
2016-12-31 35.38% ₩104.11 Billion
≈ $70.55 Million
₩294.30 Billion
≈ $199.44 Million
+32.29pp
2015-12-31 3.08% ₩7.20 Billion
≈ $4.88 Million
₩233.57 Billion
≈ $158.29 Million
-9.54pp
2014-12-31 12.63% ₩12.28 Billion
≈ $8.32 Million
₩97.25 Billion
≈ $65.90 Million
--
pp = percentage points

About Hugel Inc

KQ:145020 Korea Biotechnology
Market Cap
$1.46 Billion
₩2.15 Trillion KRW
Market Cap Rank
#7122 Global
#162 in Korea
Share Price
₩199300.00
Change (1 day)
+6.52%
52-Week Range
₩168500.00 - ₩296500.00
All Time High
₩388000.00
About

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more